Nutrivert

Nutrivert creates a postbiotics that provides an alternative to antibiotics. The company's postbiotic is a formulation of a feed additive that increases livestock feed conversion efficiency, enabling customers to get better output from their livestock.

<div>Nutrivert is a Canadian biotechnology firm specializing in developing non-antibiotic growth promotants for livestock. It has developed a proprietary product known as Nutrivert LDPP, which is designed to improve livestock health and feed efficiency without relying on antibiotics. This product mimics a cell wall component released by all bacteria, which is a postbiotic compound that reduces gut inflammation and promotes better growth and feed conversion. Nutrivert LDPP claims to deliver the growth effects of antibiotics without the use of actual antibiotics and has shown potential to protect against respiratory viral diseases like the flu, providing dual benefits for animal and potentially human health.</div>

Driving livestock productivity using next-generation biotechnology

Livestock Biotech

<div>
 
 Nutrivert is a Canadian biotechnology firm specializing in developing non-antibiotic growth promotants for livestock. It has developed a proprietary product known as Nutrivert LDPP, which is designed to improve livestock health and feed efficiency without relying on antibiotics. This product mimics a cell wall component released by all bacteria, which is a postbiotic compound that reduces gut inflammation and promotes better growth and feed conversion. Nutrivert LDPP claims to deliver the growth effects of antibiotics without the use of actual antibiotics and has shown potential to protect against respiratory viral diseases like the flu, providing dual benefits for animal and potentially human health.
 
 
 
 
 Funding and financials
 
 
 
 In March 2023, Nutrivert raised USD 1.5 million in venture funding led by Cultiv8. These funds were earmarked for further development and commercialization of its non-antibiotic livestock products.
 
</div>

<div>
 
 Aviabiotic (formerly Chicken Probiotic) is a biotechnology company innovating in poultry health. The company specializes in creating probiotics engineered for enhanced thermostability, elimination of antibiotic resistance, and dependency on corn sugar, making them environmentally friendly. These probiotics are designed specifically for integrated poultry operations, addressing both health and efficiency in poultry production.
 
 
 
 
 Funding and financials
 
 
 
 
 Aviabiotic's latest funding was a grant received in 2020, which has facilitated the development and commercialization of its specialized probiotics.&nbsp;
 
 
 
</div>

Aviabiotic

<div>
 
 ZeaVaxx is an animal healthcare company using advanced biotechnology to improve vaccine effectiveness for animals. Its plant-derived nanoparticle adjuvant platform claims to offer advantages over aluminum-based ones that are falling short in current animal vaccine formulations due to low efficacy and compatibility issues. This platform is designed to enhance the immunogenicity of vaccines to ensure that the vaccines can provoke a stronger and more effective immune response in animals.
 
 
 
 
 ZeaVaxx flagship product, Zea-11, is a proprietary glucan-based nanoparticle derived from plants. Zea-11 claims to offer simplified extraction and chemical finalization, making it the first economically viable nanoparticle adjuvant for animal vaccines.&nbsp;
 
 
 
 
 Funding and financials
 
 
 
 
 In June 2018, the company secured USD 50,000 in pre-seed funding from the Purdue Ag-celerator.
 
 
 
</div>

ZeaVaxx

<div>
 
 Malcisbo, a spin-off from the Swiss Federal Institute of Technology Zurich (ETH Zurich), is a Swiss biotechnology company developing novel vaccines for animal and human health. The company focuses on glycoengineering technologies to create efficient glycoconjugate vaccines to address bacterial diseases that impact animal health, human food safety, and zoonotic diseases.
 
 
 
 
 Its primary product offerings target Campylobacter infections in humans (to reduce food poisoning from chicken meat) and Actinobacillus pleuropneumoniae (to reduce economic losses in the swine industry due to mortality, growth retardation, and the need for antibiotics).
 
 
 
 
 Funding and financials
 
 
 
 
 As of May 2024, the company had been awarded 10 grants totaling CHF 3.5 million (~USD 3.8 million).
 
 
 
</div>

Malcisbo

<div>
 
 eggXYt is an Israeli biotech company that specializes in ultrasound technology for eggs. The company has developed a non-invasive, pre-incubation sex detection technology for chicken embryos, named seXYt, which allows poultry farmers to separate male and female layer chicks before incubation. This process claims to prevent unnecessary incubation of over 8 billion male layer chicks annually, which are otherwise disposed of after birth due to their unsuitability for the industry. These eggs are then repurposed and used outside the food industry, leading to lower costs and reduced resource waste in hatcheries.
 
 
 
 
 Key customers and partnerships
 
 
 
 
 In November 2020, the company signed an R&amp;D licensing agreement with Tropic Biosciences to develop Avian influenza resistance in chickens through gene editing.
 
 
 
 
 Funding and financials
 
 
 
 
 eggXYt has received over USD 2.5 million in funding from the European Union through the Horizon 2020 SME Program for its sex detection technology and to expand its research into new areas such as disease resistance in poultry.
 
 
 
</div>

eggXYt

<div>
 
 BioRefic is a Latvian biotech company that develops biorefinery technology to produce advanced prebiotic ingredients and microbial Omega-3 fatty acids. It primarily serves the animal feed and aquaculture sectors by providing sustainable alternatives to traditional feed ingredients. Biorefic&rsquo;s products, which include xylooligosaccharide prebiotic (a gut microbiome enhancing ingredient to improve health and immunity and boost performance), are designed to enhance animal health and efficiency, thus reducing the overall environmental impact of agriculture.
 
 
 
 
 Funding and financials
 
 
 
 
 BioRefic has raised a total of EUR 250,000 in funding over two rounds, with its most recent funding coming from a non-equity assistance round supported by RootCamp. 
 
 
 
</div>

BioRefic

Companies that offer solutions that edit (gene editing) or modify (gene modification) an animal's genome in a precise and targeted manner using methods such as TALEN's, CRISPR/Cas9, recombinant retroviruses, and sperm-mediated DNA transfer. The techniques change the existing genome to improve/express desired traits in livestock. The segment also covers companies that use an AI-based platform or otherwise to offer diagnostic testing services of the animal's genome that help livestock farmers identify genetic changes or diseases present in herds.

Companies that offer next-generation vaccines based on developments in DNA technology (e.g., mRNA vaccines) and biotechnology. The segment also includes medicines developed for the prevention and treatment of livestock diseases.

Companies that use a range of genetic techniques that can alter the DNA of animals more precisely than traditional breeding techniques. Techniques such as gender selection via sexed semen, genomic selection, or even gene editing methods like CRISPR are used to breed animals precisely with superior genetic traits.

Companies that produce natural ingredients or biological additives that can be added to animal feed for purposes such as improving nutrient uptake and the gut microbiome.

Biotech solutions to grow livestock that are of better traits and sustainable

Uses AI/machine learning to facilitate their platform/biotech processes like gene editing

Offers customization of genes and traits as required by farmers

Nutrivert

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless